Somerset Pharmaceuticals, Inc. is concerned about the treatment outcome for patients with Parkinson's disease and understands the importance of long-term treatment in helping to improve Parkinson's disease management. The Eldepryl V.I.P. (Value In Persistency) Program is designed specifically to help patients get the most from their Parkinson's disease therapy.
The Eldepryl V.I.P. Program not only helps patients remain persistent with their prescribed therapy, but also helps with other aspects of overall disease management -- helping them obtain the greatest benefit from their treatment. The materials provided through the Eldepryl V.I.P. Program are designed to effectively complement the physician's efforts to educate patients about Parkinson's disease and the unique role of Eldepryl® Capsules, 5mg (selegiline hydrochloride) in their Parkinson's disease treatment regimen.
The Educational Value of V.I.P.
- Provides educational materials, including V.I.P. Connections, a newsletter for patients. The V.I.P. newsletter features book reviews, exercises, practical advice, research news, and a patient forum. V.I.P. educational materials encourage patients to become more knowledgeable about Parkinson's disease and remain persistent with their therapy by helping them:
- Understand the benefits of long-term Eldepryl therapy
- Create appropriate treatment expectations
- Learn more about Parkinson's disease and take a more active role in managing its symptoms
- Shares experiences of other patients for peer support
- Helps provide patients with answers to commonly asked questions about Parkinson's disease and Eldepryl treatment
- Includes helpful daily living tips and other Parkinson's disease support information
The Therapeutic Value of V.I.P.
- Helps patients understand the importance of maintaining Parkinson's disease therapy for the long term
- By enhancing patient persistency with Eldepryl® Capsules, 5mg (selegiline hydrochloride), the program helps patients obtain the greatest benefit from their Eldepryl therapy
- Patients who are persistent with their treatment may have an improved therapeutic outcome and a better prognosis
- Persistency with Eldepryl therapy may help minimize disability and, thereby, may reduce disease-related costs1
Enroll now to receive member benefits
1Bryson HM, Milne RJ, Chrisp P. Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease. PharmacoEconomics. 1992;2:118-136.